CA2953709A1 - Succinate dehydrogenase inhibitors (sdhi's) - Google Patents

Succinate dehydrogenase inhibitors (sdhi's) Download PDF

Info

Publication number
CA2953709A1
CA2953709A1 CA2953709A CA2953709A CA2953709A1 CA 2953709 A1 CA2953709 A1 CA 2953709A1 CA 2953709 A CA2953709 A CA 2953709A CA 2953709 A CA2953709 A CA 2953709A CA 2953709 A1 CA2953709 A1 CA 2953709A1
Authority
CA
Canada
Prior art keywords
succinate
prodrug
acceptable salt
pharmaceutically acceptable
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2953709A
Other languages
English (en)
French (fr)
Inventor
Edward CHOUCHANI
Thomas Krieg
Kourosh SAEB-PARSY
Michael Patrick Murphy
Lorraine WORK
Christian Frezza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
United Kingdom Research and Innovation
Original Assignee
Medical Research Council
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council, Cambridge Enterprise Ltd filed Critical Medical Research Council
Publication of CA2953709A1 publication Critical patent/CA2953709A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2953709A 2014-07-03 2015-07-03 Succinate dehydrogenase inhibitors (sdhi's) Abandoned CA2953709A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1411937.4 2014-07-03
GBGB1411937.4A GB201411937D0 (en) 2014-07-03 2014-07-03 Succinate dehydrogenase inhibitors (SDH's)
PCT/GB2015/051949 WO2016001686A1 (en) 2014-07-03 2015-07-03 SUCCINATE DEHYDROGENASE INHIBITORS (SDHi's)

Publications (1)

Publication Number Publication Date
CA2953709A1 true CA2953709A1 (en) 2016-01-07

Family

ID=51410633

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2953709A Abandoned CA2953709A1 (en) 2014-07-03 2015-07-03 Succinate dehydrogenase inhibitors (sdhi's)

Country Status (10)

Country Link
US (1) US10603298B2 (https=)
EP (1) EP3164126B1 (https=)
JP (1) JP2017519020A (https=)
CN (1) CN106714793B (https=)
AU (1) AU2015282424A1 (https=)
CA (1) CA2953709A1 (https=)
GB (1) GB201411937D0 (https=)
SG (1) SG11201610588UA (https=)
WO (1) WO2016001686A1 (https=)
ZA (1) ZA201608844B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200375963A1 (en) * 2017-02-10 2020-12-03 Health Research, Inc. Targeting mitochondrial complex ii to reduce effects of chronic hypoxia
WO2019139831A1 (en) * 2018-01-10 2019-07-18 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using succinate
WO2020041470A1 (en) * 2018-08-21 2020-02-27 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods of metabolic regulation of mitochondria for treating neural injury and neurological disorders using dsh inhibitors
CN109793760B (zh) * 2019-02-13 2022-07-19 中国人民解放军总医院 琥珀酸弧菌属在预防或治疗高原病药物中的用途
GB201918022D0 (en) * 2019-12-09 2020-01-22 Cambridge Entpr Ltd Treatment or prevention of Ischaemic Stroke Reperfusion Injury
US11813239B2 (en) * 2020-02-18 2023-11-14 Wisconsin Alumni Research Foundation Compositions and methods for improving cardiac structure and/or function
GB202108594D0 (en) 2021-06-16 2021-07-28 Cambridge Entpr Ltd Treatment or prevention of ischaemia reperfusion injury
WO2025125766A1 (en) 2023-12-12 2025-06-19 Cambridge Enterprise Limited Treatment or prevention of ischaemia reperfusion injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021565A1 (en) 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
EP1686979A4 (en) * 2003-11-07 2010-03-03 Jackson H M Found Military Med ACTIVATION OF HYPOXIA-INDUCIBLE GENE EXPRESSION
WO2008039085A1 (en) 2006-09-28 2008-04-03 University Of Otago Triphenylphosphonium thionitrite nitric oxide donors
US8835510B2 (en) * 2010-06-08 2014-09-16 Montefiore Medical Center Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins
US9931313B2 (en) * 2012-04-04 2018-04-03 Beth Israel Deaconess Medical Center, Inc. Methods of treating proliferative disorders with malate or derivatives thereof
US20140128352A1 (en) * 2012-09-20 2014-05-08 Buck Institute For Research On Aging Compounds and methods for modulating mitochondrial metabolism and reactive oxygen species production
US10104882B2 (en) * 2013-04-29 2018-10-23 Montefiore Medical Center Methods and compositions for preventing and treating electrophile-mediated toxicities

Also Published As

Publication number Publication date
CN106714793A (zh) 2017-05-24
EP3164126A1 (en) 2017-05-10
WO2016001686A1 (en) 2016-01-07
EP3164126B1 (en) 2021-02-24
AU2015282424A1 (en) 2017-01-12
SG11201610588UA (en) 2017-01-27
US10603298B2 (en) 2020-03-31
US20170135977A1 (en) 2017-05-18
CN106714793B (zh) 2020-12-01
GB201411937D0 (en) 2014-08-20
ZA201608844B (en) 2019-04-24
JP2017519020A (ja) 2017-07-13

Similar Documents

Publication Publication Date Title
US10603298B2 (en) Succinate dehydrogenase inhibitors (SDHi's)
Chouchani et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
AU2023201669A1 (en) Compositions and methods for modulating hair growth
US20240156790A1 (en) Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
RU2664532C2 (ru) Пиразоламидное соединение и его применения в медицине
ES2650562T3 (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades
CA3105506A1 (en) Dimeric immuno-modulatory compounds against cereblon-based mechanisms
Aldi et al. Histamine H4-receptors inhibit mast cell renin release in ischemia/reperfusion via protein kinase Cε-dependent aldehyde dehydrogenase type-2 activation
WO2019001379A1 (zh) 用于抑制激酶活性的吲唑类化合物及其组合物及应用
TW201536748A (zh) 茀－醯胺化合物及其醫藥用途
Huang et al. O 2-sulfonylethyl protected isopropylamine diazen-1-ium-1, 2-diolates as nitroxyl (HNO) donors: Synthesis, β-elimination fragmentation, HNO release, positive inotropic properties, and blood pressure lowering studies
Zhuang et al. Design, synthesis, and antihypertensive activity of curcumin-inspired compounds via ACE inhibition and vasodilation, along with a bioavailability study for possible benefit in cardiovascular diseases
EP4053108A1 (en) Compound containing benzene ring and application thereof
JPS60501409A (ja) ポリヒドロキシ安息香酸誘導体
US20140256670A1 (en) Azidothymidine quinoline conjugated compound, preparation method therefor and application thereof in anti-hepatoma therapy
Fickentscher et al. Stereochemical properties and teratogenic activity of some tetrahydrophthalimides
US10501471B1 (en) Compounds useful for treating cardiovascular diseases
US9505753B2 (en) Inhibitors of D-amino acid oxidase
TW201702253A (zh) 磷酸肌酸類似物前藥、其組成物及用途
US9545387B2 (en) Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes
RU2428414C2 (ru) Способ получения амидов креатина
CA2887420A1 (en) Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases
JP4912574B2 (ja) シトルリン血症治療剤
Trancotă et al. 01 Acute administration of magnesium orotate at reperfusion improves mitochondrial respiration in isolated rat hearts
US10399946B2 (en) Solid forms of an S-Nitrosoglutathione reductase inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200630

FZDE Discontinued

Effective date: 20221129